Stability of Reconstituted Fibrinogen Concentrate in Hemostatic Function and Concentration

被引:1
|
作者
Peng, Henry T. [1 ]
Beckett, Andrew [2 ,3 ]
机构
[1] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON M3K 2C9, Canada
[2] McGill Univ, Dept Natl Def, Montreal, PQ H3Z 2G5, Canada
[3] Royal Canadian Med Serv, Dept Natl Def, Ottawa, ON K1A 0K2, Canada
关键词
D O I
10.1093/milmed/usaa409
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Canadian Armed Forces adopted fibrinogen concentrate (RiaSTAP) for hemostatic resuscitation in the far-forward combat setting, given its potential benefits of reducing blood loss, blood transfusion and mortality, and its long storage stability and high portability. The current guidance recommends that RiaSTAP should be administered within 8 hours after reconstitution when stored at room temperature. However, little information about its stability is available. There is also a need to investigate the stability and efficacy of RiaSTAP after reconstitution and exposure to extreme temperatures in which our forces may operate. Materials and Methods: RiaSTAP was reconstituted as per manufacturer's instruction and stored at specific temperatures (-20 degrees C, 4 degrees C, 22 degrees C, 35 degrees C, 42 degrees C, or 50 degrees C) for up to 6 months. Reconstituted RiaSTAP was also oscillated on a rocker at 18 rpm under 22 degrees C and 50 degrees C. Its hemostatic function was measured using rotational thromboelastometry performed with RiaSTAP-spiked whole blood. Fibrinogen concentrations were measured by a commercial enzyme-linked immunosorbent assay (ELISA) kit. Gel electrophoresis was also conducted for initial and stored samples. Results: We found no change to the hemostatic function of reconstituted RiaSTAP after storage at -20 degrees C for 6 months. At 4 degrees C, no obvious changes to the hemostatic effect of reconstituted RiaSTAP relative to 0 hours were seen until 1,680 hours. At 22 degrees C, a remarkable decrease began after storage for 168 hours. Storage at 35 degrees C significantly decreased the hemostatic effect after 144 hours, while the storage at 42 degrees C resulted in decreased hemostatic function after 72 hours. Finally, storage at 50 degrees C for 8 hours resulted in complete loss of hemostatic function. Compared to the hemostatic activity, the fibrinogen concentration for reconstituted RiaSTAP showed less change over time. No apparent decline in fibrinogen concentration was seen after storage at -20 degrees C for 6 months and at 4 degrees C for 1,680 hours. At 22 degrees C, there were no clear alterations until 792 hours. There was a decline in fibrinogen concentration at 35 degrees C and 42 degrees C after 672 and 600 hours of storage, respectively. At 50 degrees C, little amount of fibrinogen was detected by ELISA at 8 hours. Similar changes in the hemostatic effect and fibrinogen concentration over time were observed under the rocking condition in comparison with the static condition at the same temperature. The gel electrophoresis confirmed fibrinogen degradation which increased with storage temperature and time. Conclusions: The stability of reconstituted RiaSTAP decreases with increasing storage temperature. The hemostatic function deteriorated before fibrinogen concentration and integrity were significantly altered at all temperatures for the study period except at 50 degrees C where there was a rapid decline in both hemostatic function and fibrinogen concentration. Sample oscillation did not significantly affect its stability. The shelf life of reconstituted RiaSTAP may, therefore, be recommended accordingly when stored at different temperatures and extended to 6 days at room temperature provided that sterility is maintained.
引用
收藏
页码:E456 / E462
页数:7
相关论文
共 50 条
  • [21] Pharmacokinetics and safety of fibrinogen concentrate
    Manco-Johnson, M. J.
    Dimichele, D.
    Castaman, G.
    Fremann, S.
    Knaub, S.
    Kalina, U.
    Peyvandi, F.
    Piseddu, G.
    Mannucci, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (12) : 2064 - 2069
  • [22] Fibrinogen concentrate in bleeding patients
    Wikkelso, Anne
    Lunde, Jens
    Johansen, Mathias
    Stensballe, Jakob
    Wetterslev, Jorn
    Moller, Ann Merete
    Afshari, Arash
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (08):
  • [23] The effect of fibrinogen concentrate on thrombocytopenia
    Velik-Salchner, C.
    Haas, T.
    Innerhofer, P.
    Streif, W.
    Nussbaumer, W.
    Klingler, A.
    Klima, G.
    Martinowitz, U.
    Fries, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (05) : 1019 - 1025
  • [24] PHARMACOKINETICS OF FIBRINOGEN CONCENTRATE FOR CHILDREN WITH CONGENITAL FIBRINOGEN DEFICIENCY
    Schwartz, Bruce
    Lohade, S.
    D'Souza, Fulton
    Latha, G.
    Khayat, Claudia
    Zekavat, O.
    Kruzhkova, Irina
    Solomon, Cristina
    Knaub, Sigurd
    Peyvandi, Flora
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S65 - S66
  • [25] Fibrinogen concentrate for management of bleeding
    Rahe-Meyer, N.
    Sorensen, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (01) : 1 - 5
  • [26] Viscometric Behavior of Reconstituted Tomato Concentrate
    Barbana, Chockry
    El-Omri, AbdelFattah
    FOOD AND BIOPROCESS TECHNOLOGY, 2012, 5 (01) : 209 - 215
  • [27] Viscometric Behavior of Reconstituted Tomato Concentrate
    Chockry Barbana
    AbdelFattah El-Omri
    Food and Bioprocess Technology, 2012, 5 : 209 - 215
  • [28] CONCENTRATION AND STABILITY OF ASCORBIC-ACID IN MARKETED RECONSTITUTED ORANGE JUICE
    SQUIRES, SR
    HANNA, JG
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 1979, 27 (03) : 639 - 641
  • [29] vWF-FVIII stability of reconstituted high purity factor VIII concentrate (Alphanate(TM)).
    Eran, H
    Xu, H
    Dimmick, D
    Cakaroglu, H
    Motokubota, T
    Herring, S
    Bhattacharya, P
    BLOOD, 1995, 86 (10) : 3462 - 3462
  • [30] Effect of Protein Content on Heat Stability of Reconstituted Milk Protein Concentrate under Controlled Shearing
    Mediwaththe, Anushka
    Huppertz, Thom
    Chandrapala, Jayani
    Vasiljevic, Todor
    FOODS, 2024, 13 (02)